What is the appropriate workup for elevated hemoglobin and hematocrit?

Workup for Elevated Hemoglobin and Hematocrit

Order JAK2 V617F mutation testing immediately as the first-line diagnostic test when hemoglobin exceeds 18.5 g/dL in men or 16.5 g/dL in women, or when hematocrit is >49% in men or >48% in women. 1, 2

Initial Laboratory Evaluation

Serum erythropoietin (EPO) measurement is the critical first test that directs your diagnostic pathway: 1

• Low EPO → suggests primary erythrocytosis (polycythemia vera) and mandates JAK2 testing 1
• Normal or elevated EPO → points to secondary causes requiring evaluation for hypoxia, sleep apnea, chronic lung disease, renal tumors, or other EPO-secreting neoplasms 1

Critical caveat: Up to 30% of confirmed polycythemia vera patients have erythropoietin values within the normal range, so a normal result does not exclude the diagnosis. 2

Molecular Testing Algorithm

First-Line Testing

• JAK2 V617F mutation detects >90–95% of polycythemia vera cases and serves as a major WHO diagnostic criterion 2, 3
• This test can be performed on whole blood or purified granulocyte DNA 3
• Do not delay testing if the patient is iron-deficient or receiving iron replacement—the assay is independent of iron status 2

Second-Line Testing (if V617F negative)

• JAK2 exon 12 mutation analysis identifies an additional 2–3% of polycythemia vera cases 2, 3
• Use purified granulocyte DNA rather than whole blood for exon 12 testing to improve sensitivity for low-burden mutations 3
• Together, V617F and exon 12 testing capture >97% of polycythemia vera patients 2

Essential Ancillary Studies

Iron studies (ferritin, transferrin saturation) must be obtained because: 2

• Iron deficiency can mask true erythrocytosis by lowering hemoglobin while red-cell mass remains elevated 2
• The red-cell count stays elevated and mean corpuscular volume is reduced (microcytosis) in iron-deficient polycythemia vera 3
• Formal diagnosis may require demonstration of WHO criteria after iron replacement 2

Arterial blood gas analysis when hypoxia is suspected as a secondary cause 1

Evaluate systematically for secondary causes: 1

• Chronic lung disease
• Obstructive sleep apnea (polycythemia prevalence 6% in severe OSA) 4
• High-altitude residence
• Renal tumors or hepatocellular carcinoma
• High-oxygen-affinity hemoglobin variants (when hereditary disorder suspected) 1

WHO Diagnostic Criteria for Polycythemia Vera

Diagnosis requires EITHER:

Pathway 1 (captures >97% of cases):

All three major criteria OR the first two major criteria plus ≥1 minor criterion 2

Major Criteria:

1. Hemoglobin ≥18.5 g/dL in men or ≥16.5 g/dL in women (or hematocrit >49% in men, >48% in women), OR sustained rise of ≥2 g/dL reaching ≥17 g/dL in men or ≥15 g/dL in women 2
2. JAK2 V617F or JAK2 exon 12 mutation 2
3. Bone marrow biopsy showing hypercellularity with trilineage growth (panmyelosis) and pleomorphic megakaryocytes 2

Minor Criteria (need ≥1):

• Subnormal serum erythropoietin below reference range 2
• Bone marrow hypercellularity with trilineage growth 2
• Endogenous erythroid colony formation in vitro 2

Pathway 2 (for JAK2-negative cases):

First major criterion (elevated hemoglobin/hematocrit) plus ≥2 minor criteria 2

When to Order Bone Marrow Biopsy

Bone marrow biopsy is indicated when: 2

• JAK2 testing (both V617F and exon 12) is negative
• Diagnosis remains equivocal after initial workup
• Hemoglobin is below WHO thresholds but clinical suspicion remains high

Expected findings in polycythemia vera: hypercellularity with panmyelosis, pleomorphic megakaryocytes forming clusters, and reduced iron stores 2

JAK2 exon 12-mutated cases typically show isolated erythroid hyperplasia without the panmyelosis characteristic of V617F-positive disease 3

Special Populations and Pitfalls

Masked polycythemia vera: A subset of patients present with normal hemoglobin/hematocrit due to blood dilution, coincidental blood loss, or iron deficiency but still harbor JAK2 mutations and have underlying polycythemia vera. 5 Order JAK2 testing in patients with unexplained thrombosis at unusual sites (portal vein, splenic vein) even when blood counts are normal. 5

Testosterone replacement therapy: Polycythemia is the most common adverse effect; current guidelines recommend discontinuing or reducing dose if hematocrit exceeds 54% (hemoglobin ≥180 g/L). 6 Repeat blood donation is often insufficient to maintain safe hematocrit levels. 6

ADPKD-related erythrocytosis: ACE inhibitors or ARBs are first-line agents to reduce erythrocytosis; if contraindicated or ineffective, institute therapeutic phlebotomy. 1

Thrombotic Risk Assessment

A hematocrit of 53% independently increases the risk of thromboembolic events regardless of underlying etiology. 1 This underscores the urgency of diagnosis and treatment initiation.